

O  
FEB 17 2006  
IAPTS

**ATTORNEY DOCKET: 2006443-0002 (formerly 2003710-0001)  
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE**

Applicant: Surolia, N. et al      Examiner: K. Weddington  
Serial No: 09/763,499      Art Unit: 1614  
Filed: 371(c) date: August 27, 2001  
For: USE OF HYDROXYDIPHENYL ETHER CLASS OF CHEMICALS, AS  
EXEMPLIFIED BY TRICLOSAN, AS AN ANTIMARIAL AND IDENTIFICATION  
OF FATTY ACID SYNTHESIS AS ITS TARGET

Mail Stop: RCE  
Commissioner for Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

**INFORMATION DISCLOSURE STATEMENT**

Pursuant to the duty of disclosure under 37 CFR §§ 1.56, 1.97 and 1.98, Applicant requests  
consideration of this Information Disclosure Statement.

**Type of Statement**

The present Information Disclosure Statement is:

- An *original* Information Disclosure Statement; or  
 A *supplemental* Information Disclosure Statement.

**Certificate of Mailing**

I certify that this correspondence is being deposited with the United States Postal Service with sufficient postage as First Class Mail in an envelope addressed to Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

2-14-06

Date

Sandra Saccoccia

Signature

Sandra Saccoccia

Name of Person Signing

02/21/2006 WABDEL1 00000001 09763499

03 FC:1806

180.00 OP

Compliance with 37 CFR § 1.97

The present Information Disclosure Statement is being filed:

- [ ] Pursuant to 37 CFR § 1.97(b); no fee or certification is required:
  - [ ] Within three months of the filing date of a national application other than a continued prosecution application under § 1.53(d);
  - [ ] Within three months of the date of entry of the national stage as set forth in § 1.491 in an international application;
  - [ ] Before the mailing of a first Office action on the merits; or
  - [ ] Before the mailing of a first Office action after the filing of a request for continued examination under § 1.114.
- [ ] Pursuant to 37 CFR § 1.97(c) after the dates listed above but before the mailing date of any of a final action under § 1.113, a notice of allowance under § 1.311, or an action that otherwise closes prosecution in the application; Applicant hereby *either*:
  - [ ] Certifies that *either*:
    - [ ] each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement; or
    - [ ] That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual

designated in § 1.56(c) more than three months prior to the filing of  
the information disclosure statement; or

- [ ] Includes herewith the fee set forth in § 1.17(p),
- [X] Pursuant to 37 CFR § 1.97(d), after the mailing date of any final action under  
§ 1.113, a notice of allowance under § 1.311, or an action that otherwise closes  
prosecution in the application; Applicant hereby *both*:
- [ ] Certifies that *either*:
- [ ] each item of information contained in the information disclosure  
statement was first cited in any communication from a foreign  
patent office in a counterpart foreign application not more than  
three months prior to the filing of the information disclosure  
statement; or
- [ ] That no item of information contained in the information  
disclosure statement was cited in a communication from a foreign  
patent office in a counterpart foreign application, and, to the  
knowledge of the person signing the certification after making  
reasonable inquiry, no item of information contained in the  
information disclosure statement was known to any individual  
designated in § 1.56(c) more than three months prior to the filing of  
the information disclosure statement; and
- [X] Includes herewith the fee set forth in § 1.17(p).

Content of the Information Disclosure Statement

Applicant hereby makes of record in the above-identified application the reference(s) listed on the attached form PTO-1449 (modified). The order of presentation of the references should not be construed as an indication of the importance of the references.

Applicant includes copies of references as indicated below:

- [X] A copy of each cited reference not indicated with an asterisk is included;
- [ ] Copies of references indicated with an asterisk on the attached form PTO-1449 are not included pursuant to 37 CFR § 1.98(d) because they were previously provided to the United States Patent Office in an Information Disclosure Statement that complies with 37 CFR § 1.98(a)-(c) and was submitted in the following patent application that is relied upon in the present case for an earlier effective filing date under 35 USC § 120:

Serial Number	Filing Date	Status

- [ ] Copies of English translations of one or more non-English references are included.

Applicant hereby makes the following additional information of record in the above-identified application:

Applicant certifies that the Information Disclosure Statement *either*:

- [X] Does not contain non-English language citations;
- [ ] Includes one or more translations of a non-English citation; or
- [ ] Does contain non-English language citations, of which the following is a concise explanation:

Remarks

The submission of this Information Disclosure Statement should not be construed as a representation that a search has been made.

The submission of this Information Disclosure Statement shall not be construed to be an admission that the information cited in the statement is, or is considered to be, material to patentability as defined in § 1.56(b) .

The submission of this Information Disclosure Statement shall not be construed as a representation that the information cited in the Statement is, or is considered to be, in fact, prior art as defined by 35 USC §102.


It is respectfully requested that:

1. The Examiner consider completely the cited information, along with any other information, in reaching a determination concerning the patentability of the present claims;
2. The enclosed form PTO-1449 be signed by the Examiner to evidence that the cited patent(s) and publication(s) has (have) been fully considered by the Patent and Trademark Office during the examination of this application; and
3. The citations for the patent(s) and publication(s) be printed on any patent which issues from this application.

Notwithstanding any statements by Applicants, the Examiner is urged to form his or her own conclusions regarding the relevance of the cited reference(s).

Respectfully submitted,


Dated: 2/14/06

  
Monica R. Gerber, M.D., Ph.D.  
Reg. No. 46.724

CHOATE, HALL & STEWART LLP  
Two International Place  
Boston, Massachusetts 02110  
(617) 248-5000  
(617) 248-4000

## SUPPL. INFORMATION DISCLOSURE STATEMENT

(Use several sheets if necessary)



Applicant: Surolia, N. et al.

Filing Date:  
371(c) date: August 27,  
2001Group:  
1614

## U.S. PATENT DOCUMENTS

Examiner's Initials	U.S. Patent No.	Applicant	Issue Date	Class	Subclass

## U.S. PATENT APPLICATIONS

Examiner's Initials:	Serial Number:	Applicant:	Filing Date:	Group:	Art Unit:

## FOREIGN PATENT DOCUMENTS


Examiner's Initials	Document No.	Country	Date	Translation	
				Yes	No

## OTHER DOCUMENTS

Examiner's Initials	Citation (Including Author, Title, Date, Pertinent Pages, Etc.)
	Bergler, et al., "Protein EnvM Is the NADH-dependent Enoyl-ACP Reductase (FabI) of <i>Escherichia coli</i> ", <i>The Journal of Biological Chem.</i> , 269(8): 5493-5496, 1994.
	Haldar, et al., "Acylation of a Plasmodium Falciparum Merozoite Surface Antigen via sn-1,2-Diacyl Glycerol", <i>The Journal of Biological Chemistry</i> , 260(8): 4969-4974, 1985.
	Heath, et al., "Broad Spectrum Antimicrobial Biocides Target the FabI Component of Fatty Acid Synthesis", <i>The Journal of Biological Chemistry</i> , 273(46): 30316-30320, 1998.
	Heath, et al., "Enoyl-Acyl Carrier Protein Reductase (fabI) Plays a Determinant Role in Completing Cycles of Fatty Acid Elongation in Escherichia Coli", <i>The Journal of Biological Chemistry</i> , 270(44): 26538-26542, 1995.
	Heath, et al., "Mechanism of Triclosan Inhibition of Bacterial Fatty Acid Synthesis", <i>The Journal of Biological Chemistry</i> , 274(16): 11110-11114, 1999.
	Levy, et al., "Molecular Basis of Triclosan Activity", <i>Nature</i> , 398: 383-384, 1999.
	Matesanz, et al., "The Cloning and Expression of Pfacs1, a Plasmodium Falciparum Fatty Acyl Coenzyme A Synthetase-1 Targeted to the Host Erythrocyte Cytoplasm", <i>J. Mol. Biol.</i> 291: 59-70, 1999.
	McConkey, et al., "Inhibition of Plasmodium Falciparum Protein Synthesis", <i>The Journal of Biological Chemistry</i> , 272(4): 2046-2049, 1997.
	McMurry, et al., "Triclosan Targets Lipid Synthesis", <i>Nature</i> , 394: 531-532, 1998.

**SUPPL. INFORMATION DISCLOSURE STATEMENT**

(Use several sheets if necessary)



Applicant: Surolia, N. et al.

Filing Date: Group:  
371(c) date: August 27, 1614  
2001

	Rock, et al., "Escherichia Coli as a Model for the Regulation of Dissociable (type II) Fatty Acid Biosynthesis", <i>Biochimica et Biophysica Acta</i> , <b>1302</b> : 1-16, 1996.
	Turnowsky, et al., "envM Genes of Salmonella Typhimurium and Escherichia Coli", <i>Journal of Bacteriology</i> , <b>171</b> (12): 6555-6565, 1989.
	Vance, et al., "Inhibition of Fatty Acid Synthetases by the Antibiotic Cerulenin", <i>Biochemical and Biophysical Research Communications</i> , <b>48</b> (3): 649-655, 1972.
	Waller, et al., "Nuclear-Encoded Proteins Target to the Plastid in Toxoplasma Gondii and Plasmodium Falciparum", <i>Proc. Natl Acad. Sci.</i> , <b>95</b> : 12352-12357, 1998.
	Weeks, et al., "Studies on the Mechanism of Fatty Acid Synthesis", <i>The Journal of Biological Chemistry</i> , <b>243</b> (6): 1180-1189, 1968.

EXAMINER

DATE CONSIDERED

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

4044353